BELEODAQ® (belinostat) for Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) - Cancer Therapy Advisor

BELEODAQ® (belinostat) for Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

This slideshow reviews drug information for BELEODAQ® (belinostat), indicated for relapsed or refractory peripheral T-cell lymphoma (PTCL).

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 7: Use in Specific Populations
Slide 9: Clinical Pharmacology
Slide 13: Warnings and Precautions
Slide 17: Clinical Safety and Efficacy
Slide 23: Drug Storage and SupplySlide 25: References

Next hm-slideshow in Slides